Catalyst, Dydo Strike Deal to Develop, Market Firdapse in Japan

Catalyst, Dydo Strike Deal to Develop, Market Firdapse in Japan

297989

Catalyst, Dydo Strike Deal to Develop, Market Firdapse in Japan

Catalyst Pharmaceuticals has teamed up with DyDo Pharma to develop and commercialize Firdapse (amifampridine) in Japan for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Under the terms of their agreement, DyDo will be responsible for funding all clinical, regulatory, marketing, and commercialization activities in Japan. In turn, Catalyst will be responsible for supplying the oral small molecule medication, as well as supporting Dydo in its efforts to seek Firdapse’s approval in the country. “DyDo Pharma’s…

You must be logged in to read/download the full post.